Department of Microbiological and Biochemical Pharmacy, School of Pharmacy, Fudan University, Shanghai, China.
Department of Pharmacology, School of Pharmacy, Fudan University, Shanghai, China.
J Ethnopharmacol. 2018 May 23;218:90-99. doi: 10.1016/j.jep.2018.02.016. Epub 2018 Feb 19.
Hottuynia cordata is an important traditional Chinese medicine for the treatment of respiratory diseases including bacterial and viral infections. Polysaccharides isolated from Houttuynia cordata (HCP), as its main ingredients, have been demonstrated to ameliorate the LPS-induced acute lung injury in mice. The study aimed to determine the protective effects of HCP on multiple organ injury in influenza A virus (IAV) H1N1 infected mice and its primary mechanisms in anti-inflammation and immune regulation.
Mice were inoculated with IAV H1N1 and then treated with 20 or 40 mg/kg/d of HCP for survival test and acute lung-gut injury test.
The treatment with HCP resulted in an increase in the survival rate of H1N1 infected mice and the protection from lung and intestine injury, accompanied with the reduced virus replication. HCP markedly decreased the concentration of pulmonary proinflammatory cytokines/chemokines and the number of intestinal goblet cells, and strengthened the intestinal physical and immune barrier, according to the increase of sIgA and tight junction protein (ZO-1) in intestine. At the same time, the inhibition of inflammation in lung and gut was related to the suppressing of the expression of TLR4 and p-NFκB p65 in lung.
These results indicated that HCP ameliorated lung and intestine injury induced by IAV attack. The mechanisms were associated with inhibition of inflammation, protection of intestinal barrier and regulation of mucosal immunity, which may be related to the regulation of gut-lung axis. As an alternative medicine, HCP may have clinical potential to treat IAV infection in human beings.
蕺菜是一种重要的传统中药，用于治疗包括细菌和病毒感染在内的呼吸道疾病。蕺菜中分离得到的多糖（HCP）作为其主要成分，已被证明可改善 LPS 诱导的小鼠急性肺损伤。本研究旨在确定 HCP 对甲型流感病毒（IAV）H1N1 感染小鼠多器官损伤的保护作用及其在抗炎和免疫调节方面的主要机制。
将小鼠接种 IAV H1N1，然后用 20 或 40mg/kg/d 的 HCP 进行治疗，以进行生存试验和急性肺-肠损伤试验。
HCP 治疗可提高 H1N1 感染小鼠的存活率，并保护其免受肺和肠损伤，同时减少病毒复制。HCP 显著降低了肺部促炎细胞因子/趋化因子的浓度和肠道杯状细胞的数量，并增强了肠道的物理和免疫屏障，表现为肠道中 sIgA 和紧密连接蛋白（ZO-1）的增加。同时，肺部和肠道的炎症抑制与肺部 TLR4 和 p-NFκB p65 表达的抑制有关。
这些结果表明，HCP 改善了 IAV 攻击引起的肺和肠损伤。其机制与抑制炎症、保护肠道屏障和调节黏膜免疫有关，这可能与肠道-肺部轴的调节有关。作为一种替代药物，HCP 可能具有治疗人类 IAV 感染的临床潜力。
